Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Reports Strong 2008 Earnings But Sharp Patent Cliffs Loom

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts question whether firm’s “string of pearls” growth strategy can offset patent hit.

You may also be interested in...



BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion

Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan

BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion

The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.

BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion

The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel